Meningioma DNA Methylation Groups Identify Biological Drivers and Therapeutic Vulnerabilities

Meningiomas are the most common primary intracranial tumors. There are no effective medical therapies for meningioma patients, and new treatments have been encumbered by limited understanding of meningioma biology. Here, we use DNA methylation profiling on 565 meningiomas integrated with genetic, transcriptomic, biochemical, proteomic and single-cell approaches to show meningiomas are composed of three DNA methylation groups with distinct clinical outcomes, biological drivers and therapeutic vulnerabilities. Merlin-intact meningiomas (34%) have the best outcomes and are distinguished by NF2/Merlin regulation of susceptibility to cytotoxic therapy. Immune-enriched meningiomas (38%) have intermediate outcomes and are distinguished by immune infiltration, HLA expression and lymphatic vessels. Hypermitotic meningiomas (28%) have the worst outcomes and are distinguished by convergent genetic and epigenetic mechanisms driving the cell cycle and resistance to cytotoxic therapy. To translate these findings into clinical practice, we show cytostatic cell cycle inhibitors attenuate meningioma growth in cell culture, organoids, xenografts and patients.

Citing Articles

Malignant Meningiomas: From Diagnostics to Treatment.

Rowbottom H, Smigoc T, Ravnik J Diagnostics (Basel). 2025; 15(5).

PMID: 40075786 PMC: 11898517. DOI: 10.3390/diagnostics15050538.

Refining prognostic stratification of atypical meningiomas: significance of chromosome 1p deletion and brain invasion.

Zanconato G, Hernandez Gamero G, Mafficini A, Pedron S, Mulone D, Alberti S Acta Neuropathol Commun. 2025; 13(1):50.

PMID: 40050905 PMC: 11883970. DOI: 10.1186/s40478-025-01973-6.

The role of meningioma integrated molecular profiling to improve patient management and disclose novel therapeutic targets.

Bertero L, Padovan M, Lombardi G Brain Commun. 2025; 7(2):fcaf088.

PMID: 40046333 PMC: 11880797. DOI: 10.1093/braincomms/fcaf088.

Stereotactic DOTATATE Positron Emission Tomography/Computed Tomography-Guided Resection of a Multiply Recurrent World Health Organization Grade 2 Parasagittal Meningioma: A Technical Case Report.

Nandoliya K, Jamshidi P, Castellani R, Tate M, Avery R, Magill S Neurosurg Pract. 2025; 4(3):e00047.

PMID: 39958795 PMC: 11809977. DOI: 10.1227/neuprac.0000000000000047.

Patient-Derived Meningioma Organoids: A Reliable Model for Studying Human Tumor Pathophysiology.

Zohdy Y, Jahangiri A, Jacob F, Aksionau A, Alawieh A, Tong A Cancers (Basel). 2025; 17(3).

PMID: 39941893 PMC: 11817449. DOI: 10.3390/cancers17030526.

References

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

Tien A, Li J, Bao X, Derogatis A, Kim S, Mehta S . A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort. Clin Cancer Res. 2019; 25(19):5777-5786. PMC: 6863147. DOI: 10.1158/1078-0432.CCR-19-0133. View

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

Bi W, Nayak L, Meredith D, Driver J, Du Z, Hoffman S . Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2021; 24(1):101-113. PMC: 8730772. DOI: 10.1093/neuonc/noab118. View

Yeo N, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D . An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods. 2018; 15(8):611-616. PMC: 6129399. DOI: 10.1038/s41592-018-0048-5. View

Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J . TERT Promoter Mutations and Risk of Recurrence in Meningioma. J Natl Cancer Inst. 2015; 108(5). PMC: 4849806. DOI: 10.1093/jnci/djv377. View

Zhang X, Groopman J, Wang J . Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1. J Cell Physiol. 2004; 202(1):205-14. DOI: 10.1002/jcp.20106. View

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

Shoshani O, Brunner S, Yaeger R, Ly P, Nechemia-Arbely Y, Kim D . Chromothripsis drives the evolution of gene amplification in cancer. Nature. 2020; 591(7848):137-141. PMC: 7933129. DOI: 10.1038/s41586-020-03064-z. View

10.

Frye M, Taddei A, Dierkes C, Martinez-Corral I, Fielden M, Ortsater H . Matrix stiffness controls lymphatic vessel formation through regulation of a GATA2-dependent transcriptional program. Nat Commun. 2018; 9(1):1511. PMC: 5904183. DOI: 10.1038/s41467-018-03959-6. View

11.

Aryee M, Jaffe A, Corrada-Bravo H, Ladd-Acosta C, Feinberg A, Hansen K . Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014; 30(10):1363-9. PMC: 4016708. DOI: 10.1093/bioinformatics/btu049. View

12.

Leclerc S, Palaniswami R, Xie B, Govindan M . Molecular cloning and characterization of a factor that binds the human glucocorticoid receptor gene and represses its expression. J Biol Chem. 1991; 266(26):17333-40. View

13.

Paramasivam N, Hubschmann D, Toprak U, Ishaque N, Neidert M, Schrimpf D . Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathol. 2019; 138(2):295-308. DOI: 10.1007/s00401-019-02008-w. View

14.

Vaahtomeri K, Karaman S, Makinen T, Alitalo K . Lymphangiogenesis guidance by paracrine and pericellular factors. Genes Dev. 2017; 31(16):1615-1634. PMC: 5647933. DOI: 10.1101/gad.303776.117. View

15.

Bolger A, Lohse M, Usadel B . Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30(15):2114-20. PMC: 4103590. DOI: 10.1093/bioinformatics/btu170. View

16.

Quinton R, DiDomizio A, Vittoria M, Kotynkova K, Ticas C, Patel S . Whole-genome doubling confers unique genetic vulnerabilities on tumour cells. Nature. 2021; 590(7846):492-497. PMC: 7889737. DOI: 10.1038/s41586-020-03133-3. View

17.

Wigle J, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn M . An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 2002; 21(7):1505-13. PMC: 125938. DOI: 10.1093/emboj/21.7.1505. View

18.

Rogers L, Barani I, Chamberlain M, Kaley T, McDermott M, Raizer J . Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2014; 122(1):4-23. PMC: 5062955. DOI: 10.3171/2014.7.JNS131644. View

19.

Kim D, Paggi J, Park C, Bennett C, Salzberg S . Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019; 37(8):907-915. PMC: 7605509. DOI: 10.1038/s41587-019-0201-4. View

20.

Prager B, Vasudevan H, Dixit D, Bernatchez J, Wu Q, Wallace L . The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies. Cancer Discov. 2020; 10(11):1722-1741. PMC: 8194360. DOI: 10.1158/2159-8290.CD-20-0160. View